Antares Pharma has acquired 1 company of its own. It has also divested 1 asset.
It’s largest disclosed sale occurred in 2021, when it sold Otrexup to Assertio Holdings for $44M. The Company’s most targeted sectors include life science (100%).
100 Princeton South, Suite 300,
Ewing, New Jersey
08628
United States,
(609) 359-3020
www.antarespharma.com
| Date | Target |
Value
$mlns |
Transaction Type | Acquirer | Seller |
SRC
Link |
||
|---|---|---|---|---|---|---|---|---|
| 2021-12-15 |
Otrexup · Life Science
, New Jersey · www.otrexup.com Otrexup is a drug-device combination single dose once weekly auto-injector containing a prescription medicine, methotrexate, which is indicated for certain adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis (pJIA), after treatment with other medicines including non-steroidal anti-inflammatory drugs (NSAIDS) have been used and did not work well. It is also used to control the symptoms of severe, resistant, disabling psoriasis in adults when other types of treatment have been used and did not work well.
|
44
2.8x REVENUE |
Divestiture |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
